Shanghai Haohai Biological Technology Co., Ltd. (HAOHAI BIOTEC) filed a Next Day Disclosure Return on 28 October 2026 detailing the latest movements in its share capital and progress of its Hong Kong–listed H-share repurchase programme.

Key Takeaways

1. No Change in Issued Share Base • Issued H shares stood unchanged at 34.78 million as of 28 October 2026. • A-share capital on the STAR Market remained at 190.20 million shares, with 3.85 million held as treasury shares. • Combined, the company continues to carry 224.98 million issued shares (excluding treasury shares).

2. Latest Buyback Activity (28 October 2026) • Repurchased 38,200 H shares on the Hong Kong Stock Exchange. • Price range: HKD 15.97 – HKD 16.10; volume-weighted average price: roughly HKD 16.08. • Cash consideration: HKD 0.61 million. • All shares bought on this date are scheduled for cancellation.

3. Cumulative 2026 H-Share Repurchases • From 20 July to 28 October 2026, the company acquired 1,062,000 H shares, all pending cancellation. • The aggregate represents 3.05% of the H-share count at the time the buyback mandate was approved on 29 May 2026. • Based on disclosed daily volumes and prices, the cumulative outlay totals approximately HKD 17.20 million, implying an average cost of about HKD 16.20 per share.

4. Repurchase Capacity and Compliance • The current mandate authorises buybacks of up to 3.48 million H shares; about 2.42 million shares (≈6.95% of the original H-share base) remain available. • The company confirmed that all repurchases comply with Hong Kong Stock Exchange Listing Rules, and a 30-day moratorium on new share issues or treasury-share sales is in effect until 27 November 2026.

5. Capital Structure Snapshot (28 October 2026) • H shares in issue (excluding treasury): 34.78 million • A shares in issue (excluding treasury): 190.20 million • Total issued shares (excluding treasury): 224.98 million • Treasury shares: 3.85 million (all A shares)

The ongoing share buyback programme continues to incrementally reduce HAOHAI BIOTEC’s free-float in Hong Kong, with more than three percent of the company’s H-share capital now awaiting cancellation.